Latest Story

AstraZenca shares fall as US advisory panel votes against breast cancer drug

By Frank Prenesti

Date: Friday 01 May 2026

(Sharecast News) - AstraZeneca shares fell on Friday after its experimental breast cancer treatment was given the thumbs down by an an advisory panel for the US Food and Drug Administration.


The FDA's Oncologic Drugs Advisory Committee (ODAC) voted three to six against recommending camizestrant, which is being...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page